Aristides Capital’s LENZ Therapeutics LENZ Stock Holding History

Aristides Capital’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,500	Closed	-$168K	–	293
2025 Q4	$168K	Buy	+10,500	New	+$306K	0.03%	222

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Aristides Capital's LENZ Position: Q1 2026 in Review

Aristides Capital sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 10,500 shares — an estimated $168K sold.

Aristides Capital first reported a position in LENZ in Q4 2025 and held it in 1 quarter. The position peaked at $168K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Aristides Capital reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
Aristides Capital sold 10,500 LENZ Therapeutics shares in Q1 2026, an estimated $168K.
Aristides Capital first reported a position in LENZ Therapeutics in Q4 2025 and held it in 1 quarter.
Aristides Capital's LENZ Therapeutics position peaked at $168K in Q4 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Aristides Capital's 13F filing for Q1 2026, filed 14 May 2026.